These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 33155940)

  • 41. Right Heart Failure as a Risk for Stroke in Patients with Chronic Obstructive Pulmonary Disease: A Case-Control Study.
    Orea-Tejeda A; Bozada-Gutiérrez K; Pineda-Juárez J; González-Islas D; Santellano-Juárez B; Keirns-Davies C; Peláez-Hernández V; Hernández-Zenteno R; Sánchez-Santillán R; Cintora-Martínez C
    J Stroke Cerebrovasc Dis; 2017 Dec; 26(12):2988-2993. PubMed ID: 28844547
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Diagnostic value of combining serum soluble ST2 and interleukin-33 for heart failure patients with preserved left ventricular ejection fraction].
    Luo NS; Zhang HF; Liu PM; Lin YQ; Huang TC; Yang Y; Wang JF
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Mar; 45(3):198-203. PubMed ID: 28316175
    [No Abstract]   [Full Text] [Related]  

  • 43. Usefulness of intermediate amino-terminal pro-brain natriuretic peptide concentrations for diagnosis and prognosis of acute heart failure.
    van Kimmenade RR; Pinto YM; Bayes-Genis A; Lainchbury JG; Richards AM; Januzzi JL
    Am J Cardiol; 2006 Aug; 98(3):386-90. PubMed ID: 16860029
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Baseline characteristics of patients with heart failure and preserved ejection fraction included in the Karolinska Rennes (KaRen) study.
    Donal E; Lund LH; Oger E; Hage C; Persson H; Reynaud A; Ennezat PV; Bauer F; Sportouch-Dukhan C; Drouet E; Daubert JC; Linde C;
    Arch Cardiovasc Dis; 2014 Feb; 107(2):112-21. PubMed ID: 24388161
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparable increase of B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide levels in patients with severe sepsis, septic shock, and acute heart failure.
    Rudiger A; Gasser S; Fischler M; Hornemann T; von Eckardstein A; Maggiorini M
    Crit Care Med; 2006 Aug; 34(8):2140-4. PubMed ID: 16763507
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Morbidity and mortality in a population of patients affected by heart failure and chronic obstructive pulmonary disease: an observational study.
    Cosentino ER; Landolfo M; Bentivenga C; Spinardi L; Esposti DD; Cicero AF; Miceli R; Bui V; Berardi E; Borghi C
    BMC Cardiovasc Disord; 2019 Jan; 19(1):20. PubMed ID: 30651063
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical evaluation of geriatric outpatients with suspected heart failure: value of symptoms, signs, and additional tests.
    Oudejans I; Mosterd A; Bloemen JA; Valk MJ; van Velzen E; Wielders JP; Zuithoff NP; Rutten FH; Hoes AW
    Eur J Heart Fail; 2011 May; 13(5):518-27. PubMed ID: 21422000
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Survival in pulmonary hypertension due to chronic lung disease: Influence of low diffusion capacity of the lungs for carbon monoxide.
    Rose L; Prins KW; Archer SL; Pritzker M; Weir EK; Misialek JR; Thenappan T
    J Heart Lung Transplant; 2019 Feb; 38(2):145-155. PubMed ID: 30391191
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
    Felker GM; Anstrom KJ; Adams KF; Ezekowitz JA; Fiuzat M; Houston-Miller N; Januzzi JL; Mark DB; Piña IL; Passmore G; Whellan DJ; Yang H; Cooper LS; Leifer ES; Desvigne-Nickens P; O'Connor CM
    JAMA; 2017 Aug; 318(8):713-720. PubMed ID: 28829876
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Usefulness of N-terminal pro-B-type natriuretic peptide increase with exercise for predicting cardiovascular mortality in patients with heart failure.
    Koç M; Bozkurt A; Acartürk E; Sahin DY; Unal I
    Am J Cardiol; 2008 Apr; 101(8):1157-62. PubMed ID: 18394451
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The prognostic value of repeated measurement of N-terminal pro-B-type natriuretic peptide in patients with chronic heart failure due to left ventricular systolic dysfunction.
    Kubánek M; Goode KM; Lánská V; Clark AL; Cleland JG
    Eur J Heart Fail; 2009 Apr; 11(4):367-77. PubMed ID: 19179406
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognostic value of sST2 and NT-proBNP at admission in heart failure with preserved, mid-ranged and reduced ejection fraction.
    Huang A; Qi X; Hou W; Qi Y; Zhao N; Liu K
    Acta Cardiol; 2018 Feb; 73(1):41-48. PubMed ID: 28944719
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Plasma activity of B-type natriuretic peptide in patients with biventricular heart failure versus those with right heart failure due to chronic obstructive pulmonary disease.
    Flessas N; Alexanian I; Parissis J; Kremastinos D; Lekakis J; Filippatos G
    J Cardiovasc Med (Hagerstown); 2014 Jun; 15(6):476-80. PubMed ID: 24983267
    [TBL] [Abstract][Full Text] [Related]  

  • 54. NT-pro-BNP during isotonic and isometric exercise in heart failure patients with preserved LV ejection fraction.
    Zdrenghea DT; Ilea M; Bodizs G; Sitar-Tăut A; Zdrenghea M; Pop D
    Clin Lab; 2014; 60(12):2055-61. PubMed ID: 25651741
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Association With Exercise Capacity, Left Ventricular Filling Pressures, Natriuretic Peptides, and Left Atrial Volume.
    Lam CS; Rienstra M; Tay WT; Liu LC; Hummel YM; van der Meer P; de Boer RA; Van Gelder IC; van Veldhuisen DJ; Voors AA; Hoendermis ES
    JACC Heart Fail; 2017 Feb; 5(2):92-98. PubMed ID: 28017355
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Chronic obstructive pulmonary disease on inpatients with heart failure. GESAIC study results].
    Recio-Iglesias J; Grau-Amorós J; Formiga F; Camafort-Babkowski M; Trullàs-Vila JC; Rodríguez A;
    Med Clin (Barc); 2010 Apr; 134(10):427-32. PubMed ID: 20149399
    [TBL] [Abstract][Full Text] [Related]  

  • 57. N-terminal pro-B-type natriuretic peptide in chronic heart failure: The impact of sex across the ejection fraction spectrum.
    Faxén UL; Lund LH; Orsini N; Strömberg A; Andersson DC; Linde C; Dahlström U; Savarese G
    Int J Cardiol; 2019 Jul; 287():66-72. PubMed ID: 31005415
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Amino-terminal pro-brain natriuretic peptide for the diagnosis of acute heart failure in patients with previous obstructive airway disease.
    Tung RH; Camargo CA; Krauser D; Anwaruddin S; Baggish A; Chen A; Januzzi JL
    Ann Emerg Med; 2006 Jul; 48(1):66-74. PubMed ID: 16781921
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
    Jabbour A; Macdonald PS; Keogh AM; Kotlyar E; Mellemkjaer S; Coleman CF; Elsik M; Krum H; Hayward CS
    J Am Coll Cardiol; 2010 Apr; 55(17):1780-7. PubMed ID: 20413026
    [TBL] [Abstract][Full Text] [Related]  

  • 60. N-terminal proB-type natriuretic peptide levels aid the diagnosis of left ventricular dysfunction in patients with severe acute exacerbations of chronic obstructive pulmonary disease and renal dysfunction.
    Ouanes I; Jalloul F; Ayed S; Dachraoui F; Ouanes-Besbes L; Fekih Hassen M; Elatrous S; Abroug F
    Respirology; 2012 May; 17(4):660-6. PubMed ID: 22348741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.